Fathom’s Post

Great read! Biologics manufacturers face the challenge of managing extensive process-critical data from diverse sources, including lab equipment, handwritten records, and third-party systems. Fathom addresses this by combining machine learning and AI with domain expertise to automate data processes. This automation enhances product quality and yield monitoring, accelerates batch releases, streamlines regulatory approvals, and speeds up the development of new therapies. By transforming complex data into a valuable asset, Fathom turns a significant challenge into a competitive advantage for life sciences manufacturers.

We’ve generated a lot of interest in antibody drug conjugate (ADC) linker design from our feature on Fierce Pharma. If you work on designing ADCs, our experts can greatly increase your chances of success. Check out the editorial below and let us know how we can support your ADC design journey. https://bit.ly/4auHIyK #ADC #BioconjugateTherapeutics #VectorLaboratories

The global Cell Culture Incubators market was valued at US$ 2441 million in 2023 and is anticipated to reach US$ 3363.8 million by 2030 witnessing a CAGR of 4.8% during the forecast period 20242030. #CellCulture #Incubators #BiomedicalResearch #Pharmaceuticals #ClinicalDiagnostics #WaterJacketIncubator #GasJacketIncubator #ScientificInnovation #MedicalResearch #GlobalMarket

Publication Spotlight: "Further Accelerating Biologics Development from DNA to IND: The Journey from COVID-19 to Non-COVID-19 Programs, Antibody Therapeutics." In this newly published review, the post-pandemic outlook of biologics development is discussed, with exclusive experience sharing and insights from WuXi Biologics. Here are what you can gain from the paper: - Acceleration strategies employed by biopharmaceutical companies worldwide during COVID-19 - WuXi Biologics’ strategies and experience in the accelerated development of more than 30 COVID-19 antibodies - WuXi Biologics’ insights and success in applying accelerated strategies in more than 30 non-COVID-19 programs - How a generic 6-month DNA-to-IND timeline is achievable for general biologics development At WuXi Biologics, we strive to continuously improve and advance the science and technologies involved in the discovery, development, and manufacturing of biologics and vaccines. To read the full paper, please visit: https://lnkd.in/eXm8iZH9 #research #science #innovation #biopharma #biotherapeutics #bioprocessing #biomanufacturing #discovery #drugdiscovery #drugdevelopment #publication

Thoughts on this? >> Thermo Fisher's new EU ultra-cold facility to boost advanced therapies development - OutSourcing-Pharma.com >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #healthcare #pharmaceutical #competitivemarketing #biotech

Thoughts on this? >> Thermo Fisher's new EU ultra-cold facility to boost advanced therapies development - OutSourcing-Pharma.com >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #healthcare #pharmaceutical #competitivemarketing

A greater understanding of molecular and cellular biology, along with a significant number of technological advancements are revolutionizing the field of biologics. Biosynth's Hans de Backer and Peter Timmerman were asked to share their extensive experience in advancements in biopharmaceutical drug discovery, development and manufacturing for the May cover story from Pharmaceutical Technology. This article, also in BioPharm International, highlights the challenges of bringing new complex bioactives to market. Some of the key points made in this article are the growing use of artificial intelligence (AI) in drug discovery and how the future of biologics is increasingly driven by both patient-specific therapies and combination therapies. See the full article at pharmtech here: https://lnkd.in/eUWJQ6hS or at biopharminternational here: https://lnkd.in/emKrDJnj #peptides #biologics #drugdiscovery #biologics #pharma #drugdevelopment

Thoughts on this? >> Thermo Fisher Scientific Opens New GMP-certified Ultra-cold Facility in the EU to Accelerate Advanced Therapies ... - Business Wire >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #competitivemarketing #healthcare #pharmaceutical #biotech

𝐁𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 𝐒𝐚𝐟𝐞𝐭𝐲 𝐓𝐞𝐬𝐭𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐰𝐨𝐫𝐭𝐡 $7.2 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2029 Download PDF Brochure @ https://lnkd.in/dW4vFTd4 The report "𝐁𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 𝐒𝐚𝐟𝐞𝐭𝐲 𝐓𝐞𝐬𝐭𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐛𝐲 𝐏𝐫𝐨𝐝𝐮𝐜𝐭 & 𝐒𝐞𝐫𝐯𝐢𝐜𝐞 (𝐂𝐨𝐧𝐬𝐮𝐦𝐚𝐛𝐥𝐞𝐬, 𝐈𝐧𝐬𝐭𝐫𝐮𝐦𝐞𝐧𝐭, 𝐒𝐞𝐫𝐯𝐢𝐜𝐞𝐬), 𝐓𝐞𝐬𝐭 𝐓𝐲𝐩𝐞 (𝐌𝐲𝐜𝐨𝐩𝐥𝐚𝐬𝐦𝐚, 𝐒𝐭𝐞𝐫𝐢𝐥𝐢𝐭𝐲, 𝐄𝐧𝐝𝐨𝐭𝐨𝐱𝐢𝐧, 𝐁𝐢𝐨𝐛𝐮𝐫𝐝𝐞𝐧, 𝐕𝐢𝐫𝐮𝐬 𝐒𝐚𝐟𝐞𝐭𝐲), 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 (𝐕𝐚𝐜𝐜𝐢𝐧𝐞𝐬, 𝐦𝐀𝐛𝐬, 𝐂𝐞𝐥𝐥 & 𝐆𝐞𝐧𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐲, 𝐁𝐥𝐨𝐨𝐝 𝐏𝐫𝐨𝐝𝐮𝐜𝐭𝐬) - 𝐆𝐥𝐨𝐛𝐚𝐥 𝐅𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐭𝐨 2029", is projected to reach USD 7.2 billion by 2029 from an estimated USD 4.2 billion in 2024, at a CAGR of 11.1% The growing development of monoclonal antibodies (mAbs) and biosimilars has significantly impacted the biologics safety testing market. With the rise in mAb therapeutics, especially for #oncology and #autoimmunediseases, there is an increased demand for stringent safety testing to ensure product quality and patient safety. The rising development of mAbs and biosimilars is propelling the growth of market. For instance, in 2024, FDA approved various biosimilars such as 𝐓𝐲𝐞𝐧𝐧𝐞 (𝐭𝐨𝐜𝐢𝐥𝐢𝐳𝐮𝐦𝐚𝐛-𝐚𝐚𝐳𝐠), 𝐉𝐮𝐛𝐛𝐨𝐧𝐭𝐢 𝐚𝐧𝐝 𝐖𝐲𝐨𝐬𝐭 (𝐝𝐞𝐧𝐨𝐬𝐮𝐦𝐚𝐛-𝐛𝐛𝐝𝐳), 𝐚𝐧𝐝 𝐒𝐢𝐦𝐥𝐚𝐧𝐝𝐢 (𝐚𝐝𝐚𝐥𝐢𝐦𝐮𝐦𝐚𝐛-𝐫𝐲𝐯𝐤). Furthermore, the rising number of approvals for antibody therapeutics is propelling the growth of market. For instance, according to the The Antibody Society, during 2023, 10 #antibodytherapeutics were granted first approvals in either the #US or #EU. Thus, increasing development of #mAbs and #biosimilars is driving the growth of market. 𝐄𝐧𝐭𝐞𝐫𝐩𝐫𝐢𝐬𝐞𝐬 𝐨𝐩𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐰𝐢𝐭𝐡𝐢𝐧 𝐭𝐡𝐢𝐬 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲: Thermo Fisher Scientific, Merck KGaA, Darmstadt, Germany, Lonza, FUJIFILM Diosynth Biotechnologies, Sartorius , Charles River Laboratories , bioMérieux , Maravai LifeSciences , WuXi AppTec , SGS Société Générale de Surveillance Holding (Deutschland) GmbH, Sotera Health Company, Samsung Biologics, GenScript, Agilent Technologies, Syngene International Limited, Eurofins Scientific Finland Oy, Laboratory Corporation of America Holdings, Bio-Rad Laboratories, QIAGEN, Promega Corporation , Catalent Pharma Solutions, Associates of Cape Cod, Inc. , Pacific BioLabs, Inc. , CLEAN BIOLOGICS , PathoQuest , ARL Bio Pharma, Frontage Laboratories, Inc , Creative Biogene, Advaxia Biologics, BioReliance, Maravai LifeSciences, SAFC

Recently, much research has highlighted the critical need for robust control strategies in monoclonal #antibody drug substance production. To begin developing control strategies, teams must first comprehensively understand the risks posed by various stress conditions during #manufacturing. These stress factors can lead to #protein modifications that impact both patient safety and product quality. ARGEN has helped teams improve monoclonal antibody development and accelerated #biopolymer formulation studies. This is done by providing scientists with a real-time, multi-stressor evaluation of aggregation, degradation, and the overall stability of biopolymers of all classes. Click here to learn more! https://lnkd.in/gyvRtDmQ